Catalogo dei prodotti della ricerca
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non- Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old male diagnosed by a pathological and molecular approach as PTCL-NOS with aberrant co-expression of the B-cell antigens CD20 and CD79a, which proved non-responsive to the addition of rituximab to standard polychemotherapy. This case highlights that the presence of CD20 in PTCL may be misleading in the diagnosis and also act as a lure for the clinician to adopt a rituximab-based treatment, the effectiveness of which is undefined as the molecular mechanisms underlying B-cell marker expression in PTCL.
Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a. A case report and review of the literature / Mangogna, A.; Cox, M. C.; Ruco, L.; Lopez, G.; Belmonte, B.; Di Napoli, A.. - In: DIAGNOSTICS. - ISSN 2075-4418. - 10:6(2020), pp. 1-12. [10.3390/diagnostics10060341]
| Titolo: | Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a. A case report and review of the literature | |
| Autori: | DI NAPOLI, Arianna (Corresponding author) | |
| Data di pubblicazione: | 2020 | |
| Rivista: | ||
| Citazione: | Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a. A case report and review of the literature / Mangogna, A.; Cox, M. C.; Ruco, L.; Lopez, G.; Belmonte, B.; Di Napoli, A.. - In: DIAGNOSTICS. - ISSN 2075-4418. - 10:6(2020), pp. 1-12. [10.3390/diagnostics10060341] | |
| Handle: | http://hdl.handle.net/11573/1446203 | |
| Appartiene alla tipologia: | 01i Case report |
File allegati a questo prodotto
| File | Note | Tipologia | Licenza | |
|---|---|---|---|---|
| Mangogna_Rituximab_2020.pdf | Versione editoriale (versione pubblicata con il layout dell'editore) |  | Open Access Visualizza/Apri |
Copyright © 2022